SCHEMBL335855

SCHEMBL335855

CCCC[NH+](CCCC)CCCC.Fc1ccc([B-](c2ccc(F)cc2)(c2ccc(F)cc2)c2ccc(F)cc2)cc1

nearest known ligand 0.38

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HTR7 P34969 1/20 0.38
PSMD14 O00487 1/20 0.34
HSP90AA1 P07900 1/20 0.34
MMP2 P08253 1/20 0.34
MC4R P32245 1/20 0.34
RAD52 P43351 1/20 0.34
HPGD P15428 1/20 0.33
HDAC3 O15379 1/20 0.33
HDAC1 Q13547 1/20 0.33
HDAC2 Q92769 1/20 0.33
GAA P10253 1/20 0.31
TRPA1 O75762 1/20 0.31
KCNH3 Q9ULD8 1/20 0.31
TSHR P16473 1/20 0.31
FFAR1 O14842 1/20 0.30
FFAR4 Q5NUL3 1/20 0.30
ACHE P22303 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL136047 0.82 HTT (0.34) HPGDTSHRACHE
SCHEMBL5181935 0.81 CA2 (0.34) TSHR
SCHEMBL6913003 0.81
SCHEMBL140047 0.80 LMNA (0.38) TSHR
SCHEMBL143787 0.80 TSHR (0.35) TSHR
SCHEMBL29846536 0.79 ACHE (0.35) HTR7ACHE
SCHEMBL6914559 0.79 TLR8 (0.35) ACHE
Tetrabuthylammonium SCHEMBL15538790 0.77 SLC22A1 (0.46) HTR7PSMD14HSP90AA1MMP2MC4R
SCHEMBL15537740 0.76 PSMD14 (0.51) PSMD14HSP90AA1MMP2MC4RRAD52
SCHEMBL15538787 0.76 PSMD14 (0.51) PSMD14HSP90AA1MMP2MC4RRAD52

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 856 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2203486-B9 RACEMOSELECTIVE SYNTHESIS OF ANSA-METALLOCENE COMPOUNDS, ANSA-METALLOCENE COMPOUNDS, CATALYSTS COMPRISING THEM, PROCESS FOR PRODUCING AN OLEFIN POLYMER BY USE OF THE CATALYSTS, AND OLEFIN HOMO- AND COPOLYMERS LUMMUS NOVOLEN TECHNOLOGY GMBH (DE) 2012-08-01 EP claimed
US-8168556-B2 Racemoselective synthesis of ansa-metallocene compounds, ansa-metallocene compounds, catalysts comprising them, process for producing an olefin polymer by use of the catalysts, and olefin homo- and copolymers LUMMUS NOVOLEN TECHNOLOGY GMBH (DE) 2012-05-01 US claimed
EP-2203486-B1 RACEMOSELECTIVE SYNTHESIS OF ANSA-METALLOCENE COMPOUNDS, ANSA-METALLOCENE COMPOUNDS, CATALYSTS COMPRISING THEM, PROCESS FOR PRODUCING AN OLEFIN POLYMER BY USE OF THE CATALYSTS, AND OLEFIN HOMO- AND COPOLYMERS LUMMUS NOVOLEN TECHNOLOGY GMBH (DE) 2012-02-29 EP claimed
US-20100261860-A1 RACEMOSELECTIVE SYNTHESIS OF ANSA-METALLOCENE COMPOUNDS, ANSA-METALLOCENE COMPOUNDS, CATALYSTS COMPRISING THEM, PROCESS FOR PRODUCING AN OLEFIN POLYMER BY USE OF THE CATALYSTS, AND OLEFIN HOMO- AND COPOLYMERS LUMMUS NOVOLEN TECHNOLOGY GMBH (DE) 2010-10-14 US claimed
EP-2203486-A1 RACEMOSELECTIVE SYNTHESIS OF ANSA-METALLOCENE COMPOUNDS, ANSA-METALLOCENE COMPOUNDS, CATALYSTS COMPRISING THEM, PROCESS FOR PRODUCING AN OLEFIN POLYMER BY USE OF THE CATALYSTS, AND OLEFIN HOMO- AND COPOLYMERS Lummus Novolen Technology Gmbh (DE) 2010-07-07 EP claimed
WO-2009054831-A1 RACEMOSELECTIVE SYNTHESIS OF ANSA-METALLOCENE COMPOUNDS, ANSA-METALLOCENE COMPOUNDS, CATALYSTS COMPRISING THEM, PROCESS FOR PRODUCING AN OLEFIN POLYMER BY USE OF THE CATALYSTS, AND OLEFIN HOMO- AND COPOLYMERS NOVOLEN TECHNOLOGY HOLDINGS, C.V. (NL) 2009-04-30 WO claimed
EP-4743473-A1 CATALYSTS FOR OLEFIN POLYMERIZATION Borealis GmbH (AT) 2026-05-20 EP disclosed
EP-4743470-A1 CATALYSTS FOR OLEFIN POLYMERIZATION Borealis GmbH (AT) 2026-05-20 EP disclosed
EP-4735486-A1 PROCESS Borealis GmbH (AT) 2026-05-06 EP disclosed
EP-4222211-B1 ETHYLENE COPOLYMERS WITH IMPROVED MELTING AND GLASS TRANSITION TEMPERATURE BOREALIS GMBH (AT) 2026-04-22 EP disclosed
US-12600807-B2 Polypropylene film with improved slip performance BOREALIS AG (AT) 2026-04-14 US disclosed
EP-4359759-B1 METHOD FOR DETERMINING COMPRESSIVE CHARACTER OF OLEFIN POLYMERISATION CATALYSTS AND OLEFIN POLYMERISATION CATALYST BOREALIS GMBH (AT) 2026-04-08 EP disclosed
EP-4722288-A1 AUTOMOTIVE COMPOSITION Borealis GmbH (AT) 2026-04-08 EP disclosed
US-6271164-B1 METALLOCENE CATALYST LYONDELL CHEMICAL TECHNOLOGY, L.P. 2001-08-07 US disclosed
US-6177526-B1 METALLOCENE; COCATALYST; MODIFIED OXIDE CONTAINS ORGANIC SILICON RADICALS CONTAINING AT LEAST ONE OF THE GROUPS NITROGEN, FLUORINE, PHOSPHORUS OR SULFUR. TARGOR GMBH (DE) 2001-01-23 US disclosed
US-6150544-A Transition metal compound and catalyst containing the same for polymerization of olefins JAPAN POLYOLEFINS CO., LTD. (JP) 2000-11-21 US disclosed
EP-0969010-A2 Transition metal compound and catalyst containing the same for polymerization of olefins Japan Polyolefins Co., Ltd. (JP) 2000-01-05 EP disclosed
EP-0714920-B1 Catalyst for polymerization of olefins NIPPON OIL CO LTD (JP) 1997-11-05 EP disclosed
EP-0768320-A1 Catalyst component and catalyst NIPPON OIL CO. LTD. (JP) 1997-04-16 EP disclosed
EP-0714920-A1 Catalyst for polymerization of olefins NIPPON OIL CO. LTD. (JP) 1996-06-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100261860-A1 RACEMOSELECTIVE SYNTHESIS OF ANSA-METALLOCENE COMPOUNDS, ANSA-METALLOCENE COMPOUNDS, CATALYSTS COMPRISING THEM, PROCESS FOR PRODUCING AN OLEFIN POLYMER BY USE OF THE CATALYSTS, AND OLEFIN HOMO- AND COPOLYMERS MAOA, SNCA, ARSA HTR7 774/4885PSMD14 1874/4885HSP90AA1 958/4885
US-12600807-B2 Polypropylene film with improved slip performance CCRL2, CCR1, CCR6 HTR7 229/4885PSMD14 3129/4885HSP90AA1 1622/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.